Gabapentin Capsule
Product Images NDC 23155-866

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 23155-866). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Cockcroft And Gault Equation (3db34064 46bf 470d Aa9a 66c363c27fa6 01)

Cockcroft And Gault Equation (3db34064 46bf 470d Aa9a 66c363c27fa6 01)
FDA Label Image

Image (3db34064 46bf 470d Aa9a 66c363c27fa6 02)

Image (3db34064 46bf 470d Aa9a 66c363c27fa6 02)
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (3db34064 46bf 470d Aa9a 66c363c27fa6 03)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (3db34064 46bf 470d Aa9a 66c363c27fa6 03)
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (3db34064 46bf 470d Aa9a 66c363c27fa6 04)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (3db34064 46bf 470d Aa9a 66c363c27fa6 04)
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (3db34064 46bf 470d Aa9a 66c363c27fa6 05)

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (3db34064 46bf 470d Aa9a 66c363c27fa6 05)
This text appears to be a description regarding the proportion of responders in controlled PHN (Postherpetic Neuralgia) studies. It shows the percentage of patients with more than 50% reduction in pain score at the endpoint of the studies. The text also includes the results of Study 1 and Study 2, along with the corresponding placebo (PBO) and GBP (unknown abbreviation) dosages. However, specific details are not clear due to the limitations of output.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (3db34064 46bf 470d Aa9a 66c363c27fa6 06)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (3db34064 46bf 470d Aa9a 66c363c27fa6 06)
FDA Label Image

Logo (3db34064 46bf 470d Aa9a 66c363c27fa6 07)

Logo (3db34064 46bf 470d Aa9a 66c363c27fa6 07)
FDA Label Image

Logo (3db34064 46bf 470d Aa9a 66c363c27fa6 08)

Logo (3db34064 46bf 470d Aa9a 66c363c27fa6 08)
FDA Label Image

Gabapentin Capsules 300mg (100S)

Gabapentin Capsules 300mg (100S)
FDA Label Image

Gabapentin Capsules 400mg (100S)

Gabapentin Capsules 400mg (100S)
FDA Label Image

Cont-label-100mg-100s (3db34064 46bf 470d Aa9a 66c363c27fa6 11)

Cont-label-100mg-100s (3db34064 46bf 470d Aa9a 66c363c27fa6 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.